Literature DB >> 2461725

Enzymatically active forms of reverse transcriptase of the human immunodeficiency virus.

F Lori1, A I Scovassi, D Zella, G Achilli, E Cattaneo, C Casoli, U Bertazzoni.   

Abstract

The reverse transcriptase of HIV-1 (AIDS virus) is characterized by the presence of two highly immunogenic proteins of 66 and 51 kD known to be enzymatically active as a complex p66/51. Using an activity gel procedure that allows identification of catalytic polypeptides in situ after PAGE in denaturing conditions, we visualized two major active bands of 66 and 51 kD of reverse transcriptase from highly purified preparations of HIV-1. We show that both p66 and p51 are enzymatically active. An additional active band was also associated with a 165 kD polypeptide, representing about 2-4% of total activity and possibly corresponding to the putative gag-pol precursor. In H9-infected cells the 66 kD active band became visible 70 hours after infection. These studies show that the two major forms of reverse transcriptase (66 and 51 kD) of HIV-1 are independently active and that a higher Mr form of 165 kD is also enzymatically active.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2461725     DOI: 10.1089/aid.1988.4.393

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  11 in total

1.  Role for human immunodeficiency virus type 1 Tat protein in suppression of viral reverse transcriptase activity during late stages of viral replication.

Authors:  M Kameoka; L Rong; M Götte; C Liang; R S Russell; M A Wainberg
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  Viral DNA carried by human immunodeficiency virus type 1 virions.

Authors:  F Lori; F di Marzo Veronese; A L de Vico; P Lusso; M S Reitz; R C Gallo
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

3.  Enzyme activities in four different forms of human immunodeficiency virus 1 pol gene products.

Authors:  Y W Hu; C Y Kang
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

4.  Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance.

Authors:  S Alireza Rabi; Gregory M Laird; Christine M Durand; Sarah Laskey; Liang Shan; Justin R Bailey; Stanley Chioma; Richard D Moore; Robert F Siliciano
Journal:  J Clin Invest       Date:  2013-08-27       Impact factor: 14.808

5.  Inhibition of human immunodeficiency virus type 1 RNase H by sulfated polyanions.

Authors:  K Moelling; T Schulze; H Diringer
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

6.  Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles.

Authors:  A H Kaplan; J A Zack; M Knigge; D A Paul; D J Kempf; D W Norbeck; R Swanstrom
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

7.  MAVS, cGAS, and endogenous retroviruses in T-independent B cell responses.

Authors:  Ming Zeng; Zeping Hu; Xiaolei Shi; Xiaohong Li; Xiaoming Zhan; Xiao-Dong Li; Jianhui Wang; Jin Huk Choi; Kuan-wen Wang; Tiana Purrington; Miao Tang; Maggy Fina; Ralph J DeBerardinis; Eva Marie Y Moresco; Gabriel Pedersen; Gerald M McInerney; Gunilla B Karlsson Hedestam; Zhijian J Chen; Bruce Beutler
Journal:  Science       Date:  2014-12-19       Impact factor: 47.728

8.  Cleavage of the HIV-1 p66 reverse transcriptase/RNase H by the p9 protease in vitro generates active p15 RNase H.

Authors:  T Schulze; M Nawrath; K Moelling
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

9.  Identification and characterization of human immunodeficiency virus type 1 gag-pol fusion protein in transfected mammalian cells.

Authors:  C Peng; N T Chang; T W Chang
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 virions composed of unprocessed Gag and Gag-Pol precursors are capable of reverse transcribing viral genomic RNA.

Authors:  A H Kaplan; P Krogstad; D J Kempf; D W Norbeck; R Swanstrom
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.